Controversial effects of non-steroidal anti-inflammatory drugs on bone: A review

Inflammation and Allergy - Drug Targets

Volumn 8, Issue 3, 2009, Pages 169-175

  Salari, Pooneh ^a   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BMD; Bone marker; Bone metabolism; COX

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 6; KETOROLAC; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOPROTEGERIN; PARACETAMOL; PARECOXIB; PLACEBO; PROSTAGLANDIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CYTOKINE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; APLASTIC ANEMIA; BLEEDING; BONE DENSITY; BONE METABOLISM; BONE MINERALIZATION; BONE TURNOVER; CLINICAL TRIAL; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; DRUG ACTIVATION; DRUG MECHANISM; DRUG OVERDOSE; DYSPEPSIA; FLUID RETENTION; FRACTURE HEALING; FRACTURE IMMOBILIZATION; HALLUCINATION; HEADACHE; HEMOLYTIC ANEMIA; HOMEOSTASIS; HUMAN; HYPERKALEMIA; INTERSTITIAL NEPHRITIS; LIVER FAILURE; LOW DRUG DOSE; MACULOPAPULAR RASH; METRORRHAGIA; MOOD DISORDER; NEUTROPENIA; NONHUMAN; OSTEOARTHRITIS; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SODIUM RETENTION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; URINE RETENTION; ANIMAL; BONE; BONE DEVELOPMENT; DRUG EFFECT; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; BONE AND BONES; CYCLOOXYGENASE INHIBITORS; CYTOKINES; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 70349332588     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152809788681065     Document Type: Review

References (75)

1. Wechter, W.J. The effects of NSAIDS and E-prostaglandins on bone: a two signal hypothesis for the maintenance of skeletal bone. Prog. Drug Res., 1992, 39, 351-64.
2. Salari, P.; Rezaei, A.; Larijani, B.; Abdollahi, M. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med. Sci. Monit., 2008, 14, RA37-RA44.
3. Abdollahi, M.; Larijani, B.; Rahimi, R.; Salari, P. Role of oxidative stress in osteoporosis. Therapy, 2005, 2, 787-96.
4. Raisz, L.G. Physiologic and pathologic roles of prostaglandins and other eicosanoids in bone metabolism. J. Nutr., 1995, 125, 2024S-2027S.
5. Dekel, S.; Lenthal, G.; Francis, M.J.O. Release of prostaglandins from bone and muscle after tibial fracture. An experimental study in rabbits. J. Bone Joint. Surg. Br., 1981, 63-B, 185-9.
6. Waters, D.J.; Caywood, D.D.; Trachte, G.J.; Turner, R.T.; Hodgson, S.F. Immobilization increases bone prostaglandin E. Effect of acetylsalicylic acid on disuse osteoporosis studied in dogs. Acta Orthop. Scand., 1991, 62, 238-43.
7. Kimble, R.B.; Bain, S.; Pacifici, R. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J. Bone Miner. Res., 1997, 12, 935-41.
8. Raisz, L.G. Physiology and pathology of bone remodeling. Clin. Chem., 1999, 45, 1353-8.
9. Sugiyama, T. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J. Bone Miner. Metab., 2001, 19, 89-96.
10. Vaes, G. Cellular biology and biochemical mechanism of bone resorption. A review of recent developments on the formation, activation, and mode of action of osteoclasts. Clin. Orthop. Relat. Res., 1988, 231, 239-71.
11. Harizi, H.; Norbert, G. Inhibition of IL-6, TNF-alpha, and cyclooxygenase-2 protein expression by prostaglandin E2-induced IL-10 in bone marrow-derived dendritic cells. Cell Immunol., 2004, 228, 99-109.
12. Dimmen, S.; Nordsletten, L.; Engebretsen, L.; Steen, H.; Madsen, J.E. Negative effects of parecoxib on bone mineral during frcture healing in rats. Acta. Orthopaedica, 2008, 79, 438-44.
13. Raisz, L.G.; Pilbeam, C.C.; Fall, P.M. Prostaglandins: mechanisms of action and regulation of production in bone. Osteoporos. Int., 1993, 3(Suppl 1), 136-40.
14. Tai, H.; Miyaura, C.; Pilbeam, C.C., Tamura, T.; Ohsugi, Y.; Koishihara, Y.; Kubodera, N.; Raisz, L.G.; Suda, T. Transcriptional induction of cyclooxygenase-2 in osteoblasts is involved in interleukin-6-induced osteoblast formation. Endocrinology, 1997, 138, 2372-9.
15. Copeland, R.A.; Williams, J.M.; Giannaras, J., Nurnberg, S.; Covington, M.; Pinto, D.; Pick, S.; Trzasko, J.M. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA, 1994, 91, 11202-6.
16. Kudo, I.; Murakami, M.; Hara, S.; Inoue, K. Mammalian non-pancreatic phospholipases A2. Biochim. Biophys. Acta, 1993, 1170, 217-31.
17. Jones, D.A.; Carlton, D.P.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, S.M. Molecular cloning of human prostaglandin endoperoxidase synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 1993, 268, 9049-54.
18. Shaftel, S.S.; Olschowka, J.A.; Hurley, S.D.; Moore, A.H.; O'Banion, M.K. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res. Mol. Brain Res., 2003, 119, 213-5.
19. Raisz, L.G. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and diseases. Am. J. Med., 2001, 110, 43S-45S.
20. Masferrer, J.L.; Zweifel, B.S.; Manning, P.T.; Hauser, P.T.; Leahy, K.M.; Smith, W.G.; Isakson, P.C.; Seibert, K. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc. Natl. Acad. Sci. USA, 1994, 91, 3228-32.
21. Shadnia, S.; Esmaily, H.; Sasanian, G.; Pajoumand, A.; Hassanian-Moghaddam, H.; Abdollahi, M. Pattern of acute poisoning in Tehran-Iran in 2003. Hum. Exp. Toxicol., 2007, 26, 753-6.
22. Shadnia, S.; Soltaninejad, K.; Heydari, K.; Sasanian, G.; Abdollahi, M.; Tramadol intoxication: a review of 114 cases. Hum. Exp. Toxicol., 2008, 27, 201-5.
23. Rauscher, M.; Center, O.R. Aspirin may help prevent, treat osteoporosis: animal study. PLoS One, 2008, 3.
24. Cooper, C.; Coupland, C.; Mitchel, M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum. Dis., 1995, 54, 49-52.
25. Cortet, B.; Flipo, R.M.; Duquesnoy, B.; Delcambre, B. Bone tissue in rheumatoid arthritis (1). Bone mineral density and fracture risk. Rev. Rhum. Engl. Ed., 1995, 62, 197-204.
26. Lane, N.E.; Pressman, A.R.; Star, V.L.; Cummings, S.R.; Nevitt, M.C. Rheumatoid arthritis and bone mineral density in elderly women. The study of osteoporotic fractures research group. J. Bone Miner. Res., 1995, 10, 257-63.
27. Flower, R.J. Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev., 1974, 26, 33-67.
28. Suponitzky, I.; Weinreb, M. Differential effects of systemic prostaglandin E2 on bone mass in rat long bones and calvariae. J. Endocrinol., 1998, 156, 51-7.
29. Weinreb, M.; Suponitzky, I.; Keila, S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone, 1997, 20, 521-6.
30. Lipsky, P.E.; Brooks, P.; Crofford, L.J.; DuBois, R.; Graham, D.; Simon, L.S.; van de Putte, L.B.; Abramson, S.B. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and diseases. Arch. Intern. Med., 2000, 160, 913-20.
31. FitzGerald, G.A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Eng. J. Med., 2001, 345, 433-42.
32. Feldman, R.S.; Szeto, B.; Chauncey, H.H.; Glodhaber, P. Non-steroidal anti-inflammatory drugs in the reduction of human alveolar bone loss. J. Clin. Periodontol., 1983, 10, 131-6.
33. Hardt, A.B. Early metabolic response of bone to immobilization. J. Bone Joint Surg. Am., 1972, 54, 119-24.
34. Jee, W.S.; Li, X.J.; Li, Y.L. Flurbiprofen-induced stimulation of periosteal bone formation and inhibition of bone resorption in older rats. Bone, 1988, 9, 381-9.
35. Lane, N.; Coble, T.; Kimmel, D.B. Effect of naproxen on cancellous bone in ovariectomized rats. J. Bone Miner. Res., 1990, 5, 1029-35.
36. Raisz, L.G. Local and systemic factors in the pathogenesis of osteoporosis. N. Engl. J. Med., 1988, 318, 818-27.
37. Lane, N.; Maeda, H.; Cullen, D.M.; Kimmel, D.B. Cancellous bone behavior in hindlimb immobilized rats during and after naproxen treatment. Bone Miner., 1994, 26, 43-59.
38. Jiang, Y.; Zhao, J.; Genant, H.K.; Dequeker, J.; Geusens, P. Bone mineral density and biomechanical properties of spine and femur of ovariectomized rats treated with naproxen. Bone, 1998, 22, 509-14.
39. Jungkeit, M.C.; Chole, R.A. Ibuprofen inhibits localized bone resorption in the middle ear. Calcif. Tissue Int., 1991, 48, 267-71.
40. Sudmann, E.; Bang, G. Indomethacin-induced inhibition of haversian remodeling in rabbits. Acta. Orthop. Scand., 1979, 50, 621-7.
41. Murakami, N.; Takase, H.; Saito, T.; Iwata, K.; Miura, H.; Naruse, T. Effects of a novel non-steroidal anti-inflammatory drug (M-5011) on bone metabolism in rats with collagen-induced arthritis. Eur. J. Pharmacol., 1998, 352, 81-90.
42. Tiseo, B.C.; Namur, G.N.; de Paula, E.J.; Junior, R.M.; de Oliveira, C.R. Experimental study of the action of COX-2 selective nonsteroidal anti-inflammatory drugs and traditional anti-inflammatory drugs in bone regulation. Clinics, 2006, 61, 223-30.
43. Myers, L.K.; Battacharya, S.D.; Herring, P.A., Xing, Z.; Goorha, S.; Smith, R.A.; Bhattacharya, S.K.; Carbone, L.; Faccio, R.; Kang, A.H.; Ballou, L.R. The isozyme-specific effects of cyclooxygenase-deficiency on bone in mice. Bone, 2006, 39, 1048-52.
44. Igarashi, K.; Woo, J.T.; Stem, P.H. Effects of a selective cyclooxygenase-2 inhibitor, celecoxib, on bone resorption and osteoclasto-genesis in vitro. Biochem. Pharmacol., 2002, 63, 523-32.
45. Kasukawa, Y.; Miyakoshi, N.; Srivastava, A.K.; Nozaka, K.; Maekawa, S.; Baylink, D.J.; Mohan, S.; Itoi, E. The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo. Tohoku J. Exp. Med., 2007, 211, 275-83.
46. Uebergang, T.N.; Bryant, B.J.; Grills, B.L. The effects of paracetamol and aspirin on immobilized rat bone. Austral. N. Z. Bone Miner. Soc. Ann. Sci. Meeting Abstr., 1996, 6, 25.
47. Aspenberg, P. Avoid cox inhibitors after skeletal surgery. Acta Orthop. Scand., 2002, 73, 489-90.
48. Gerstenfeld, L.C.; Thiede, M.; Seibert, K.; Mielke, C.; Phippard, D.; Svagr, B.; Cullinane, D.; Einhorn, T.A. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J. Orthop. Res., 2003, 21, 670-5.
49. Einhorn, T.A. Di inhibitors of cyclooxygenase-2 impair bone healing? J. Bone Miner. Res., 2002, 17, 977-8.
50. Dahners, L.E.; Mullis, B.H. Effects of nonsteroidal antiinflammatory drugs on bone formation and soft-tissue healing. J. Am. Acad. Orthop. Surg., 2004, 12, 139-43.
51. Simon, A.M.; O'Connor, J.P. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J. Bone Joint Surg. Am., 2007, 89, 500-11.
52. Stewart, A.; Black, A.J. Bone mineral density in osteoarthritis. Curr. Opin. Rheumatol., 2000, 12, 464-7.
53. Bhandari, M.; Schemitsch, E.H. Bone formation following intramedullary femoral reaming is decreased by indomethacin and antibodies ti insulin-like growth factors. J. Orthop. Trauma, 2002, 16, 717-22.
54. Brown, K.M.; Saunders, M.M.; Kirsch, T.; Donahue, H.J.; Reid, J.S. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J. Bone Joint Surg. Am., 2004, 86-A, 116-23.
55. Endo, K.; Sairyo, K.; Komatsubara, S.; Sasa, T.; Egawa, H.; Yonekura, D.; Adachi, K.; Ogawa, T.; Murakami, R.; Yasui, N. Cyclooxygenase-2 inhibitor inhibits the fracture healing. J. Physiol. Anthropol. Appl. Human Sci., 2002, 21, 235-8.
56. H_́Osgevold, H.E.; Gr_́Osgaard, B.; Reikerš, O. Effects of short-term treatment with corticosteroids and indomethacin on bone healing. A mechanical study of osteotomies in rats. Acta Orthop. Scand., 1992, 63, 607-11.
57. Beck, A.; Krischak, G.; Sorg, T.; Augat, P.; Farker, K.; Merkel, U.; Kinzl, L.; Claes, L. Influence of diclofenac (group of nonsteroidal anti-inflammatory drugs) on fracture healing. Arch. Orthop. Trauma Surg., 2003, 123, 327-32.
58. Ho, M.L.; Chang, J.K.; Chuang, L.Y.; Hsu, H.K.; Wang, G.J. Effects of nonsteroidal anti-inflammatory drugs and prostaglandins on osteoblastic function. Biochem. Pharmacol., 1999, 58, 983-90.
59. Krischak, G.D.; Augat, P.; Blakytny, R.; Claes, L.; Kinzl, L.; Beck, A. The non-steroidal anti-inflammatory drug diclofenac reduces appearance of osteoblasts in bone defect healing in rats. Arch. Orthop. Trauma Surg., 2007, 127, 453-8.
60. Shamir, D.; Keila, S.; Weinreb, M. A selective EP4 receptor antagonist abrogates the stimulation of osteoblast recruitment from bone marrow stromal cells by prostaglandin E2 in vivo and in vitro. Bone, 2004, 34, 157-62.
61. Carbone, L.D.; Tylavsky, F.A.; Cauley, J.A.; Harris, T.B.; Lang, T.F.; Bauer, D.C.; Barrow, K.D.; Kritchevsky, S.B. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J. Bone Miner. Res., 2003, 18, 1795-802.
62. Bauer, D.C.; Orwoll, E.S.; Fox, K.M.; Vogt, T.M.; Lane, N.E.; Hochberg, M.C.; Stone, K.; Nevitt, M.C. Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. Study of Osteoporotic Fracture Research Group. J. Bone Miner. Res., 1996, 11, 29-35.
63. Morton, D.J.; Barrett-Connor, E.L.; Schneider, D.L. Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bernardo study. J. Bone Miner. Res., 1998, 13, 1924-31.
64. Van Staa, T.P.; Leufkens, H.G.; Cooper, C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone, 2000, 27, 563-8.
65. Bell, N.H.; Hollis, B.W.; Shary, J.R.; Eyre, D.R.; Eastell, R.; Colwell, A.; Russell, R.G. Diclofenac sodium inhibits bone resorption in postmenopausal women. Am. J. Med., 1994, 96, 349-53.
66. Jeffcoat, M.K.; Reddy, M.S.; Haigh, S.; Buchanan, W.; Doyle, M.J.; Meredith, M.P.; Nelson, S.L.; Goodale, M.B.; Wehmeyer, K.R. A comparison of topical ketorolac, systemic flurbiprofen, and placebo for the inhibition of bone loss in adult periodontitis. J. Periodontol., 1995, 66, 328-39.
67. Kehoe, M.J.; Cohen, S.M.; Zarrinnia, K.; Cowan, A. The effect of acetaminophen, ibuprofen, and misoprostol on prostaglandin E2 synthesis and the degree and rate of orthodontic tooth movement. Angle Orthodont., 1996, 66, 339-50.
68. Lane, N.E.; Bauer, D.; Pressman, A.; Nevitt, M.C.; Cummings, S.R. Effect of nonsteroidal anti-inflammatory drugs on bone resorption: a cross-sectional study. J. Bone Miner. Res., 1995, 10 [Suppl. 1], S467.
69. Howell, T.H.; Williams, R.C. Nonsteroidal anti-inflammatory drugs as inhibitors of periodontal disease progression. Crit. Rev. Oral Biol. Med., 1993, 4, 177-96.
70. Lane, N.E.; Bauer, D.C.; Nevitt, M.C.; Pressman, A.R.; Cummings, S.R. Aspirin and nonsteroidal anti-inflammatory drug use in elderly women: effects on a marker of bone resorption. The Study of Osteoporotic Fractures Research Group. J. Rheumatol., 1997, 24, 1132-6.
71. Head, J.E.; Bryant, B.J.; Grills, B.L.; Ebeling, P.R. Effects of short-term use of ibuprofen or acetaminophen on bone resorption in healthy men: a double-blind, placebo-controlled pilot study. Bone, 2001, 29, 437-41.
72. Brooks, P.M.; Day, R.O. Nonsteroidal anti-inflammatory drugs-differences and similarities. N. Eng. J. Med., 1991, 324, 1716-25.
73. Salari, P.; Larijani, B.; Abdollahi, M. Association of hyperhomo-cysteinemia with osteoporosis: a systematic review. Therapy, 2008, 5, 215-222.
74. Yousefzadeh, G.; Larijani, B.; Mohammadirad, B.; Heshmat, R.; Dehghan, G.; Rahimi, R.; Abdollahi, M. Determination of oxidative stress and concentration of TGF-beta 1 in the blood and saliva of osteoporotic subjects. Ann. N. Y. Acad. Sci., 2006, 1091, 142-150.
75. Hasani-Ranjbar, S.; Larijani, B.; Abdollahi, M. A systematic review of the potential herbal sources of future drugs effective in oxidant-related diseases. Inflamm. Allergy Drug Targets, 2009, 8, 2-10.